Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Arbutus Biopharma Corp (ABUS)

Arbutus Biopharma Corp (ABUS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 850,072
  • Shares Outstanding, K 192,324
  • Annual Sales, $ 6,170 K
  • Annual Income, $ -69,920 K
  • EBIT $ -47 M
  • EBITDA $ -45 M
  • 60-Month Beta 0.66
  • Price/Sales 137.44
  • Price/Cash Flow N/A
  • Price/Book 10.94

Options Overview Details

View History
  • Implied Volatility 267.76% (+47.59%)
  • Historical Volatility 44.15%
  • IV Percentile 98%
  • IV Rank 77.65%
  • IV High 331.14% on 11/05/25
  • IV Low 47.59% on 01/22/25
  • Expected Move (DTE 11) 0.09 (1.88%)
  • Put/Call Vol Ratio 0.02
  • Today's Volume 54
  • Volume Avg (30-Day) 229
  • Put/Call OI Ratio 0.32
  • Today's Open Interest 47,409
  • Open Int (30-Day) 48,077
  • Expected Range 4.44 to 4.61

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.07
  • Growth Rate Est. (year over year) +1,427,242.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.08 +10.78%
on 11/20/25
4.87 -7.19%
on 11/12/25
+0.02 (+0.44%)
since 11/07/25
3-Month
4.01 +12.58%
on 09/09/25
5.10 -11.37%
on 09/11/25
+0.43 (+10.51%)
since 09/08/25
52-Week
2.70 +67.41%
on 04/09/25
5.10 -11.37%
on 09/11/25
+0.84 (+22.83%)
since 12/06/24

Most Recent Stories

More News
Arbutus: Q3 Earnings Snapshot

Arbutus: Q3 Earnings Snapshot

ABUS : 4.52 (+2.26%)
Arbutus Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Strong financial position with cash, cash equivalents and marketable securities of $93.7M     Moderna litigation U.S. trial scheduled for March 2026; Favorable claim construction ruling...

ABUS : 4.52 (+2.26%)
Arbutus Biopharma Showcases Data at Liver Meeting 2025

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Arbutus Biopharma...

ABUS : 4.52 (+2.26%)
Arbutus Announces Four Abstracts Accepted for Presentation at AASLD - The Liver Meeting® 2025

Multiple abstracts accepted featuring imdusiran clinical data  – highlighting progress toward a potential functional cure for chronic hepatitis B virus AB-101 clinical data abstract recognized as...

ABUS : 4.52 (+2.26%)
Arbutus: Q2 Earnings Snapshot

Arbutus: Q2 Earnings Snapshot

ABUS : 4.52 (+2.26%)
Arbutus Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Q2 total revenue of $10.7M includes previously-deferred revenue following reacquisition of Greater China rights to imdusiran Dr. Roger Sawhney joins the Arbutus Board of Directors following resignation...

ABUS : 4.52 (+2.26%)
Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus

ABUS : 4.52 (+2.26%)
Arbutus: Q1 Earnings Snapshot

Arbutus: Q1 Earnings Snapshot

ABUS : 4.52 (+2.26%)
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update

ABUS : 4.52 (+2.26%)
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025

ABUS : 4.52 (+2.26%)

Business Summary

Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly...

See More

Key Turning Points

3rd Resistance Point 4.76
2nd Resistance Point 4.65
1st Resistance Point 4.59
Last Price 4.52
1st Support Level 4.42
2nd Support Level 4.31
3rd Support Level 4.25

See More

52-Week High 5.10
Last Price 4.52
Fibonacci 61.8% 4.18
Fibonacci 50% 3.90
Fibonacci 38.2% 3.62
52-Week Low 2.70

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar